HAEMOPHILIA AND OTHER CONGENITAL COAGULOPATHIESNew developments in the diagnosis of primary immune thrombocytopeniaLozano, Maria L. Author Information Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain Correspondence to Maria L. Lozano, PhD, MD, Hospital General Universitario Morales Meseguer, Servicio de Hematología y Oncología Médica, Avda. Marqués de los Vélez, s/n, 30008 Murcia, Spain Tel: +34 968 34 19 90; fax: +34 968 23 24 84; e-mail: [email protected] Received 6 April, 2021 Accepted 1 May, 2021 Blood Coagulation & Fibrinolysis: January 2022 - Volume 33 - Issue - p S5-S7 doi: 10.1097/MBC.0000000000001095 Buy Metrics Abstract Immune thrombocytopenia is an acquired autoimmune disorder, which can affect both adults and children, characterized by lower than normal platelet counts (below 100 × 109/l). Thrombocytopenia may result in an increased risk of bleeding and puts patients at risk for serious complications. In the last decade, the multifactorial pathogenesis of ITP has become apparent, leading to greater understanding that different immune-mediated mechanisms could be involved in each patient, explaining the variable clinical presentation and response to therapies. The management of ITP patients has changed considerably in these past 10 years, but diagnosis of the disease has changed little, and remains clinical and possible only with the exclusion of other causes of thrombocytopenia. Although the search for such a test continues, to date, there is no reliable biomarker or gold-standard diagnostic test, which contributes to the high rate of misdiagnosis of the disease. This review presents the current limitations in the identification of the molecular disease underlying this disorder. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.